RxSight, Inc.

RXST Nasdaq SEC CIK 1111485
Follow RxSight Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $24.5M −19.1% vs same quarter last year
Net income −$16.2M −65.3% vs same quarter last year
EPS, diluted −$0.39 −62.5% vs same quarter last year
Operating cash flow $45.2M +3909.3% vs same quarter last year
Revenue by quarter
$40.2M
$37.9M
$33.6M
$30.3M
$32.6M
$30.9M
$27.2M
$24.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100M$150MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$134.5M−$38.9
FY24$139.9M−$27.5
FY23$89.1M−$48.6
FY22$49M−$66.8
FY21$22.6M−$48.7M
FY20$14.7M$27.6M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400%−200%0%200%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2576.6%−35.8%0%
FY2470.7%−26.3%0%
FY2360.4%−56.2%0%
FY2243.5%−129.2%0%
FY2120%−233.6%−215.5%
FY2011.6%−241.3%187.9%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$19.3M
FY24−$22.4M
FY23−$46.4M
FY22−$61.2M
FY21−$46.6M
FY20−$37.7M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • RxSight
  • Healthcare median
−400%−200%0%200%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRxSightHealthcare median
FY250%−30.6%
FY240%−47%
FY230%−58%
FY220%−80.4%
FY21−215.5%−71.9%
FY20187.9%−62.2%
FY19-−46.3%